Claims

1. A medicament comprising an immunoconjugate that binds to FOLR1 for use in treating a cancer that expresses FOLR1 polypeptide, wherein administration of the medicament produces a Cmax of 100-150 μg/mL.

2. The use of an immunoconjugate that binds to FOLR1 in the manufacture of a medicament for the treatment of a cancer that expresses FOLR1 polypeptide wherein the medicament upon administration, produces a Cmax of 100-150 μg/mL.

3. The use of claim 2, wherein the immunoconjugate is to be administered at a dose of about 3 mg/kg to about 6 mg/kg.

4. The use-of claim 3, wherein the immunoconjugate is to be administered at a dose of about 3.0 mg/kg, about 3.3 mg/kg, about 5.0 mg/kg, about 5.5 mg/kg, or about 6.0 mg/kg.

5. The use of claim 2, wherein the immunoconjugate is to be administered about once every week.

6. The use of any one of claims 2-5, wherein the immunoconjugate comprises an antibody or antigen-binding fragment thereof comprising a light chain CDR1 comprising SEQ ID NO:6, a light chain CDR2 comprising SEQ ID NO:7, a light chain CDR3 comprising SEQ ID NO:8, a heavy chain CDR1 comprising SEQ ID NO:9, a heavy chain CDR2 comprising SEQ ID NO: 10 or 11, and a heavy chain CDR3 comprising SEQ ID NO:12.

7. The use of claim 6, wherein the immunoconjugate comprises an antibody or antigen-binding fragment thereof comprising a variable light chain comprising SEQ ID NO:5 and a variable heavy chain comprising SEQ ID NO:3.

8. The use of claim 7, wherein the immunoconjugate comprises an (a) antibody or antigen-

binding fragment thereof that comprises (i) a heavy chain comprising the same amino acid sequence as the amino acid sequence of the heavy chain encoded by the plasmid deposited with the American Type Culture Collection (ATCC) as PTA-10772 and (ii) a light chain comprising the same amino acid sequence as the amino acid sequence of the light chain encoded by the plasmid deposited with the ATCC as PTA-10774; (b) a sulfo-SPDB linker; and (c) DM4.

9. The use of any one of claims 2-8, wherein the immunoconjugate is to be administered intravenously.

10. The use of any one of claims 2-9, wherein cancer is selected from the group consisting of ovarian cancer, brain cancer, breast cancer, uterine cancer, endometrial cancer, pancreatic cancer, renal cancer, cancer of the peritoneum, and lung cancer.

11. The use of claim 10, wherein the lung cancer is non small cell lung cancer or bronchiolo-alveolar carcinoma.

12. The use of claim 10, wherein the ovarian cancer is epithelial ovarian cancer, platinum resistant ovarian cancer, relapsed ovarian cancer, or refractory ovarian cancer.

13. The use of claim 2, wherein the FOLR1 expression levels are measured by immunehisto-chemistry (IHC).

14. The use of any one of claims 2-13, wherein the medicament is for co-administration with a steroid, wherein the steroid is optionally dexamethasone.

15. The use of any one of claims 2-14, wherein the administration results in a decrease in tumor size or a decrease in CA125.

16. The use of claim 6, wherein the antibody or antigen-binding fragment thereof comprises (i) a heavy chain comprising SEQ ID NO:13 and (ii) a light chain comprising SEQ ID

NO:15.

17. The use of claim 6, wherein the antibody or antigen-binding fragment thereof comprises (i) a heavy chain comprising the same amino acid sequence as the amino acid sequence of the heavy chain encoded by the plasmid deposited with the American Type Culture Collection (ATCC) as PTA-10772 and (ii) a light chain comprising the same amino acid sequence as the amino acid sequence of the light chain encoded by the plasmid deposited with the ATCC as PTA-10774.

18. The use of claim 2, wherein the immunoconjugate is to be administered about once every three weeks.